scholarly journals Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: a SEER Population-Based Analysis

2021 ◽  
Author(s):  
Xiaoyi Lin ◽  
Xin Lin ◽  
Guangnan Wei ◽  
Jiali Lin ◽  
Ning Liao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cumulative Incidence ◽  
Competing Risk ◽  
Her2 Status ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Risk Of Death ◽  
Her2 Positivity ◽  
Bronchus Cancer

Abstract Background: The survival improvement in breast cancer (BC) renders the long-termsurvivorsan increasedprobability of second primary malignancy (SPM), and thus excess mortality. Although previous evidence has indicated various predictorsofSPM, little is known whether SPM incidencevaries by HER2 status of first BC. Methods: Based on BC patients registered between 2010-2018 in the NCI SEER database, we utilized standardized incidence ratio (SIR) and Poisson regression to quantify SPM occurrence compared with the general population. Then, adjusted for competing death risk, cumulative incidence function and Gray’s test were adopted to estimate the probability of SPM. Subsequent proportional subdistribution hazards regression was executedto identify the HER2 status impact on SPM risk. Finally, survival analysiswas performed.Results: A total of 409,796 first BC patients were includedand 18,283 were identified with at least one SPM. The SIR of SPM after HER2+ BC was significantly lower than HER2- BC (1.03 vs 1.13; RR, 0.92; 95% CI, 0.88-0.96; p<0.001). But the predominantly declining SPM risk was only observed for second BC (RR, 0.89; 95% CI, 0.82-0.96; p=0.003) and lung and bronchus cancer (RR, 0.84; 95% CI, 0.74-0.95; p=0.007). Further competing risk analysis verified the protective effect of HER2 positivity status on SPM occurrence.The 5-year cumulative incidence of SPM following HER2+ and HER2- BC were 5.16% and 4.09%, respectively (p<0.001). In addition, among patients suffering from SPM,HER2 positivity status contributed tobetter overall survival. Conclusion: After considering intrinsic incremental risk with age and adjusting for competing risk of death, our study demonstrated that HER2+ BC patients had lower SPM occurrence, remarkable for second BC and lung and bronchus cancer. The disparity implies the relation between SPM occurrence and therapeutic along with genetic factors underlying BC HER2 status.

scholarly journals Family history of breast cancer as a second primary malignancy in relatives: a nationwide cohort study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Guoqiao Zheng ◽  
Jan Sundquist ◽  
Kristina Sundquist ◽  
Jianguang Ji
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Family History ◽  
Cumulative Incidence ◽  
Second Primary ◽  
Endocrine Gland ◽  
Primary Cancer ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
History Of

Abstract Background With the increasing number of breast cancer (BC) diagnosed as a second primary malignancy after a first primary non-breast cancer (BCa-2), it is unclear about the familial risk of BC among women with a first-degree relative (FDR, parents or siblings) affected by a BCa-2. Methods In this Swedish nationwide cohort study, 5315 women with a FDR affected by BCa-2 and 115,048 women with a FDR affected by BC as the first primary cancer (BCa-1) were followed for the first primary invasive BC diagnosis. Relative risk (RR) of BC was estimated through Poisson regression by using 2,743,777 women without a family history of cancer as reference. The risk was stratified by the diagnostic age of BC in FDR, proband type, the time interval between the first primary cancer and BCa-2 in FDR as well as the site of first primary cancer diagnosed in FDR before BCa-2. We also calculated the cumulative incidence of BC from birth to a specific age for the three groups. Results The cumulative incidence from birth to age 70 was 10% among women with a family history of BCa-2. The RR of BC with a family history of BCa-2 (RR, 1.68, 95%CI, 1.49 to 1.88) was comparable to that with BCa-1 (1.68, 1.63 to 1.73). The risk was largely consistent irrespective of proband type. The age of onset of BCa-2 in FDR (RR early-onset, 1.72 vs. RR late-onset 1.67) had less influence on the risk compared to BCa-1 in FDR (1.89 vs. 1.63). In the analysis stratified by the time between the first primary cancer and BCa-2 in relatives, the risks were largely similar. For the site of first primary cancer diagnosed in FDR before BCa-2, the increased BC risk was found in women whose FDRs were diagnosed with first primary gastric, colorectal, endometrial, ovarian, nervous system and endocrine gland cancers, and non-Hodgkin lymphoma. Conclusions Women with a family history of BCa-2 have a similar overall BC risk as those with a family history of BCa-1. The risk varied according to the site of first primary cancer diagnosed in FDR before BCa-2.

Characteristics and survival of secondary male breast cancer: SEER database analysis.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13690-e13690
Author(s):  
John Khoury ◽  
Siddhartha Yadav ◽  
Tara Rangarajan ◽  
Dana Zakalik
Keyword(s):  
Breast Cancer ◽  
Male Breast Cancer ◽  
Hormone Receptors ◽  
Latency Period ◽  
Male Breast ◽  
Stage I ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Increased Risk

e13690 Background: Male breast cancer (MBC) is rare accounting for less than 0.5% of all cancer diagnoses in men. We used the term secondary male breast cancer (sMBC) to refer to ipsilateral and contralateral recurrences in addition to new primary MBC. Given its low incidence, data regarding the risk of developing sMBC and its characteristics are scarce. Methods: Multiple Primary Standardized Incidence Ratios (MP-SIR) session was conducted from the SEER*Stat software. We included all patients diagnosed with stage I,II and III MBC between 1990 to 2015 from the Surveillance Epidemiology and End Results (SEER) 18 registry. The standardized incidence ratio (SIR) was calculated as an estimate of the risk of a second primary malignancy based on the incidence in the general population. Descriptive statistics and Kaplan-Meier analysis were performed using SPSS software. Results: Among all 2321 men diagnosed with a first primary MBC during the study period, 28 patients had a subsequent diagnosis of MBC. The risk of sMBC was significantly elevated with SIR of 33.12 (95% CI, 22.18 – 47.56). The median latency period between the initial and subsequent diagnoses was 5.9 years. 82.1% of the patients were White, 14.3% Black and 3.6% Asian/Pacific Islander. Majority of the cases constituting 85.7% of sMBC were diagnosed in the contralateral breast. 67.8% of the sMBC remained hormone receptors status positive similar to the initial status of the primary diagnosis. 42.9% of the sMBC patients were diagnosed with stage I, 17.9% with stage II, 3.6% with stage III, 17.9% with stage IV and 17.9% of unknown stage. The median overall survival for sMBC was 96 months (95% CI, 11.3-180.6). We also found an increased risk of developing liver cancer (SIR: 2.16), prostate cancer (SIR: 1.29), thyroid cancer (SIR: 3.08) and acute myeloid leukemia (SIR: 2.4) in individuals after a diagnosis of MBC. Conclusions: Men diagnosed with breast cancer are at increased risk of sMBC in addition to other malignancies which require careful monitoring after completing initial treatment. Contralateral mammogram screening or prophylactic contralateral mastectomy can be considered based on patient’s preferences and values.

scholarly journals A Competing-Risk Nomogram Predicting Second Primary Malignancy in Hepatocellular Carcinoma Survivors

2020 ◽  
Author(s):  
Xuqi Sun ◽  
Jinbin Chen ◽  
Juncheng Wang ◽  
Zhongguo Zhou ◽  
Li Xu ◽  
...  
Keyword(s):  
Risk Model ◽  
Extrahepatic Bile Duct ◽  
Competing Risk ◽  
Second Primary ◽  
Second Primary Malignancy ◽  
Primary Malignancy ◽  
Predicting Model ◽  
System P ◽  
Surgical History ◽  
Second Primary Malignancies

Abstract Background:Hepatocellular carcinoma (HCC) survivors are increasing due to the improvement of survival. Follow-up scheme to prevent recurrence is routinely recommended, but are these patients exposed to increased risks of second malignancies remains unknown. We aimed to identify risk factors for second primary malignancies (SPM) among HCC survivors and develop a predicting model accordingly. Methods: We identified HCC patients in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2014. For the incidence of specific SPMs, standardized incidence ratios (SIRs) were calculated. The proportional hazard model was performed in order to discover hazards of SPM, and a competing-risk nomogram was developed to stratify patients with different incidences for SPM. Results:The crude incidence of SPM was 2.70% in HCC survivors, with the SIR of 1.09. HCC survivors had significantly higher incidences of SPM in the following sites: oral cavity and pharynx, stomach, intra and extrahepatic bile duct, lung and bronchus, kidney and renal pelvis, thyroid and lymphatic system (p< 0.05). Patients with diagnosed age at 61-75 years old, smaller tumor size, better histologic differentiation, earlier AJCC stage or surgical history had higher risks for SPM. The c-index of the competing-risk nomogram was 0.663. The cumulative incidences of SPM were significantly different among each quartile of patients stratified by the predicting model (p< 0.05). Conclusion:HCC survivors had an excess risk for SPMs, especially those with promising prognostic factors. This nomogram was the first competing-risk model for identifying high-risk cohort and assist clinical screening.

Sign in / Sign up

Export Citation Format

Share Document